Second-Line Docetaxel Benefits Seen For Esophagogastric Cancers

SAN FRANCISCO (IMNG) - Results of a phase III trial support a common clinical practice - giving docetaxel as second-line chemotherapy to patients with advanced adenocarcinomas of the stomach or esophagus...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news